Developer docs
API playgroundTry for free, no card

Search company profiles

Epicrispr Biotechnologies

Full company profile

uuid004d3es

Namestring
Epicrispr Biotechnologies
Legal namestring
Epicrispr Biotechnologies, Inc.
Websiteurl
epicrispr.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Epicrispr Biotechnologies is a clinical-stage biotechnology company developing in vivo gene therapies that modulate gene expression through epigenetic editing rather than cutting DNA. Its proprietary Gene Expression Modulation System (GEMS) is a modular platform that combines compact DNA-binding proteins (including the exclusively licensed CasMINI, the smallest dCas protein functional in human cells, and the proprietary CasONYX), customized guide RNAs, and a library of transcriptional and epigenomic modulators (histone modifiers, DNA methylators/demethylators, chromatin remodelers) to either dial up or down expression of disease-causing genes. The company's lead candidate, EPI-321, is an AAV-delivered therapy designed to re-methylate the D4Z4 region and suppress toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD); it entered a global Phase 1/2 trial in 2025 and has reported interim data showing statistically significant increases in lean muscle volume. Two additional pipeline programs, EPI-331 for Duchenne Muscular Dystrophy (mutation-agnostic utrophin upregulation) and EPI-141 for autosomal dominant retinitis pigmentosa 4 (suppress-and-replace), apply the same GEMS architecture to other rare genetic diseases.

The company is headquartered in South San Francisco, California, was spun out of Stanford University in 2018 by CRISPR pioneer Lei Stanley Qi, Ph.D., and officially launched in July 2022 with a $55 million Series A led by Horizons Ventures; Amber Salzman, Ph.D., serves as CEO. As of the most recent disclosures, Epicrispr operates with approximately 41 team members and has raised a total of approximately $123 million across its Series A and a $68 million Series B in March 2025 led by Ally Bridge Group with participation from SOLVE FSHD. The business model is pre-commercial: Epicrispr is not yet generating product revenue and instead funds operations through venture capital and a research collaboration with Kite Pharma to engineer next-generation CAR T-cell therapies using GEMS. The company partners with Forge Biologics for AAV cGMP manufacturing and with Springbok Analytics for AI-powered MRI biomarker analysis, and has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for EPI-321 as the first and only open epigenetic editing IND authorized in the US.

Short descriptiontext

Epicrispr Biotechnologies is a clinical-stage biotech developing in vivo epigenetic editing therapies using its GEMS platform, with lead candidate EPI-321 in Phase 1/2 trials for facioscapulohumeral muscular dystrophy and pipeline programs in Duchenne and retinitis pigmentosa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic gene therapy, gene expression modulation, CRISPR-based therapeutics, rare neuromuscular disease, AAV gene therapy
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Epigenetic Gene Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Developing proprietary epigenetic therapies targeting genetic diseases. Revenue expected from future therapeutic product sales upon regulatory approval.

epicrispr.com
2Research Collaborations
TypeLicensing Royalties
Description

Strategic research collaboration with Kite Pharma to develop next-generation CAR T-cell therapies using Epicrispr's epigenetic editing technology.

epicrispr.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Epicrispr Biotechnologies is a clinical-stage biotechnology company that develops and commercializes epigenetic gene therapies using its proprietary Gene Expression Modulation System (GEMS) platform, which combines compact DNA-binding proteins (CasMINI, CasONYX), customized guide RNAs, and epigenomic modulators to precisely dial gene expression up or down without altering DNA. Its lead clinical asset, EPI-321, is an AAV-delivered epigenetic therapy that re-methylates the D4Z4 region to suppress toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD), currently in Phase 1/2 trials with positive interim muscle volume data. The pipeline additionally includes EPI-331 for Duchenne Muscular Dystrophy and EPI-141 for autosomal dominant Retinitis Pigmentosa 4.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Statistically significant increases in whole-body lean muscle volume - average ~370mL (~0.8 pounds) with individual gains from 0.5 to 1.3 pounds, some muscles gaining 15% lean muscle volume at 6 months
+4 more records
Product overview1 text field

Epicrispr Biotechnologies is a clinical-stage company pioneering epigenetic editing therapies using its proprietary Gene Expression Modulation System (GEMS) platform. The GEMS platform combines compact DNA-binding proteins (including CasMINI with exclusive license), guide RNAs, and epigenetic modulators to create customizable gene expression modulation therapies. Lead clinical program EPI-321 (FSHD, Phase 1/2) is in active clinical trials with positive interim data. Pipeline includes EPI-331 (DMD) and EPI-141 (RP4). The platform enables mutation-agnostic treatments that can dial up or down gene expression without permanently altering DNA.

Product and service4 records
1EPI-321
CategoryGene therapy product candidate
Description

EPI-321 is an AAV-delivered (AAVrh74) one-time IV infusion epigenetic gene therapy for adults with genetically confirmed FSHD1 that re-methylates the D4Z4 region to suppress toxic DUX4 expression, addressing the underlying genetic cause of FSHD. Delivered as a single intravenous infusion and the first and only open epigenetic editing IND authorized in the US, with FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.

2EPI-331
CategoryGene therapy product candidate
Description

EPI-331 is a preclinical-stage epigenome editing therapy for Duchenne Muscular Dystrophy (DMD) that uses the GEMS platform with CRISPR-based components to upregulate utrophin (UTRN) gene expression as a mutation-agnostic treatment strategy, working regardless of the specific dystrophin mutation a patient carries. Designed for pediatric and young male DMD patients; targeting rare X-linked muscle disorder affecting approximately 1 in 3,500-5,000 live male births.

3EPI-141
CategoryGene therapy product candidate
Description

EPI-141 is a preclinical AAV-delivered gene therapy for autosomal dominant Retinitis Pigmentosa 4 (adRP4) that uses a "suppress and replace" strategy to block mutated rhodopsin gene expression while providing a healthy rhodopsin DNA sequence via a single AAV vector. Indication affects 5,000-8,000 people in the US with no available therapies.

4GEMS Platform (Gene Expression Modulation System)
CategoryTechnology platform
Description

The GEMS Platform is Epicrispr's proprietary modular epigenetic editing platform that combines DNA-binding proteins (including exclusively licensed CasMINI and proprietary CasONYX), customized guide RNAs (designed using the APPRAISR machine learning model), and a library of epigenomic modulators (transcriptional activators and repressors, histone modifiers, DNA (de)methylators, chromatin remodelers) to precisely modulate gene expression without altering DNA. Enables mutation-agnostic, customizable therapies via mix-and-match architecture and is the underlying technology licensed to Kite Pharma for CAR T-cell engineering.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-05
Description

AAV development and manufacturing partnership. Forge Biologics' Columbus, Ohio facility provides adeno-associated virus process development, analytical development, and cGMP manufacturing for EPI-321.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-23
Description

Partnership to integrate AI-powered muscle MRI imaging and analysis into EPI-321 first-in-human clinical trial. Springbok provides automated segmentation and quantification of muscle volume, fat content, and inflammation across dozens of muscle groups.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-31
Description

Collaboration to develop next-generation CAR T-cell therapies for cancer. Kite tapped Epicrispr's epigenetic editing technology to engineer T cells by modulating gene expression.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical research center in New Zealand conducting EPI-321 first-in-human trial in partnership with Epicrispr. Principal investigator Dr. Richard Roxburgh at University of Auckland.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Tune Therapeutics is an epigenetic editing company developing tunable gene-expression therapies using CRISPR-based platforms. Direct competitor in the same therapeutic modality with overlapping target disease areas including rare genetic disorders.

TypeEmerging player
Description

Shape Therapeutics develops RNA editing and AAV-delivered genetic medicines, including platforms that combine RNA editing with epigenetic regulation. Adjacent technology category with shared delivery (AAV) and rare-disease focus, but differentiated at the editing modality.

TypeBroad incumbent
Description

Ultragenyx is a rare-disease-focused biotech with a broad gene therapy and biologics pipeline, including neuromuscular and metabolic programs. Board member Eric Crombez serves as CMO, creating a strategic relationship; competes for the same rare-disease patient populations.

TypeBroad incumbent
Description

Sarepta is the established gene therapy leader for Duchenne muscular dystrophy (DMD), with multiple approved therapies including AAV-delivered Elevidys. Represents the dominant competitor in Epicrispr's EPI-331 DMD indication with deep commercial infrastructure.

TypeBroad incumbent
TypeDirect peer
Description

Omega Therapeutics is an epigenomic programming company developing DNA-encoded regulatory medicines that target genomic "insulators" to tune gene expression. Closely comparable platform approach to GEMS for precise gene-expression modulation without DNA alteration.

TypeDirect peer
Description

Chroma Medicine is a direct competitor developing an epigenetic editing platform using dCas9 fused to chromatin regulators, targeting genetic diseases and oncology. Highly comparable technology stack to Epicrispr's GEMS, including mix-and-match epigenetic modulator approach.

TypeDirect peer
Description

Solid Biosciences is a clinical-stage gene therapy company focused on Duchenne muscular dystrophy and other neuromuscular diseases. Directly competes with EPI-331 in DMD using AAV-delivered approaches, with overlapping clinical and regulatory pathways.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epicrispr Biotechnologies

Epigenetic Gene Therapyepicrispr.com

Epicrispr Biotechnologies is a clinical-stage biotech developing in vivo epigenetic editing therapies using its GEMS platform, with lead candidate EPI-321 in Phase 1/2 trials for facioscapulohumeral muscular dystrophy and pipeline programs in Duchenne and retinitis pigmentosa.

What Epicrispr Biotechnologies does

Epicrispr Biotechnologies is a clinical-stage biotechnology company developing in vivo gene therapies that modulate gene expression through epigenetic editing rather than cutting DNA. Its proprietary Gene Expression Modulation System (GEMS) is a modular platform that combines compact DNA-binding proteins (including the exclusively licensed CasMINI, the smallest dCas protein functional in human cells, and the proprietary CasONYX), customized guide RNAs, and a library of transcriptional and epigenomic modulators (histone modifiers, DNA methylators/demethylators, chromatin remodelers) to either dial up or down expression of disease-causing genes. The company's lead candidate, EPI-321, is an AAV-delivered therapy designed to re-methylate the D4Z4 region and suppress toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD); it entered a global Phase 1/2 trial in 2025 and has reported interim data showing statistically significant increases in lean muscle volume. Two additional pipeline programs, EPI-331 for Duchenne Muscular Dystrophy (mutation-agnostic utrophin upregulation) and EPI-141 for autosomal dominant retinitis pigmentosa 4 (suppress-and-replace), apply the same GEMS architecture to other rare genetic diseases.

The company is headquartered in South San Francisco, California, was spun out of Stanford University in 2018 by CRISPR pioneer Lei Stanley Qi, Ph.D., and officially launched in July 2022 with a $55 million Series A led by Horizons Ventures; Amber Salzman, Ph.D., serves as CEO. As of the most recent disclosures, Epicrispr operates with approximately 41 team members and has raised a total of approximately $123 million across its Series A and a $68 million Series B in March 2025 led by Ally Bridge Group with participation from SOLVE FSHD. The business model is pre-commercial: Epicrispr is not yet generating product revenue and instead funds operations through venture capital and a research collaboration with Kite Pharma to engineer next-generation CAR T-cell therapies using GEMS. The company partners with Forge Biologics for AAV cGMP manufacturing and with Springbok Analytics for AI-powered MRI biomarker analysis, and has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for EPI-321 as the first and only open epigenetic editing IND authorized in the US.

Epicrispr Biotechnologies firmographics

Firmographics
Name
Epicrispr Biotechnologies
Legal name
Epicrispr Biotechnologies, Inc.
Website
https://epicrispr.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Epicrispr Biotechnologies is a clinical-stage biotech developing in vivo epigenetic editing therapies using its GEMS platform, with lead candidate EPI-321 in Phase 1/2 trials for facioscapulohumeral muscular dystrophy and pipeline programs in Duchenne and retinitis pigmentosa.
Ownership category
akta.pro rank

Epicrispr Biotechnologies industry classification

Industry
Product category
Epigenetic Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Epigenetic gene therapy
  • Gene expression modulation
  • CRISPR-based therapeutics
  • Rare neuromuscular disease
  • AAV gene therapy

Where Epicrispr Biotechnologies is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epicrispr Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Development and Commercialization: Pre-revenue clinical-stage biotech company. Developing proprietary epigenetic therapies targeting genetic diseases. Revenue expected from future therapeutic product sales upon regulatory approval.
  2. Research Collaborations: Strategic research collaboration with Kite Pharma to develop next-generation CAR T-cell therapies using Epicrispr's epigenetic editing technology.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Epicrispr Biotechnologies product offering

Product offering

Core offering

Epicrispr Biotechnologies is a clinical-stage biotechnology company that develops and commercializes epigenetic gene therapies using its proprietary Gene Expression Modulation System (GEMS) platform, which combines compact DNA-binding proteins (CasMINI, CasONYX), customized guide RNAs, and epigenomic modulators to precisely dial gene expression up or down without altering DNA. Its lead clinical asset, EPI-321, is an AAV-delivered epigenetic therapy that re-methylates the D4Z4 region to suppress toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD), currently in Phase 1/2 trials with positive interim muscle volume data. The pipeline additionally includes EPI-331 for Duchenne Muscular Dystrophy and EPI-141 for autosomal dominant Retinitis Pigmentosa 4.

Product overview

Epicrispr Biotechnologies is a clinical-stage company pioneering epigenetic editing therapies using its proprietary Gene Expression Modulation System (GEMS) platform. The GEMS platform combines compact DNA-binding proteins (including CasMINI with exclusive license), guide RNAs, and epigenetic modulators to create customizable gene expression modulation therapies. Lead clinical program EPI-321 (FSHD, Phase 1/2) is in active clinical trials with positive interim data. Pipeline includes EPI-331 (DMD) and EPI-141 (RP4). The platform enables mutation-agnostic treatments that can dial up or down gene expression without permanently altering DNA.

Differentiator

Problem solved

Functional benefit

Products and services

  • EPI-321 EPI-321 is an AAV-delivered (AAVrh74) one-time IV infusion epigenetic gene therapy for adults with genetically confirmed FSHD1 that re-methylates the D4Z4 region to suppress toxic DUX4 expression, addressing the underlying genetic cause of FSHD. Delivered as a single intravenous infusion and the first and only open epigenetic editing IND authorized in the US, with FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.
  • EPI-331 EPI-331 is a preclinical-stage epigenome editing therapy for Duchenne Muscular Dystrophy (DMD) that uses the GEMS platform with CRISPR-based components to upregulate utrophin (UTRN) gene expression as a mutation-agnostic treatment strategy, working regardless of the specific dystrophin mutation a patient carries. Designed for pediatric and young male DMD patients; targeting rare X-linked muscle disorder affecting approximately 1 in 3,500-5,000 live male births.
  • EPI-141 EPI-141 is a preclinical AAV-delivered gene therapy for autosomal dominant Retinitis Pigmentosa 4 (adRP4) that uses a "suppress and replace" strategy to block mutated rhodopsin gene expression while providing a healthy rhodopsin DNA sequence via a single AAV vector. Indication affects 5,000-8,000 people in the US with no available therapies.
  • GEMS Platform (Gene Expression Modulation System) The GEMS Platform is Epicrispr's proprietary modular epigenetic editing platform that combines DNA-binding proteins (including exclusively licensed CasMINI and proprietary CasONYX), customized guide RNAs (designed using the APPRAISR machine learning model), and a library of epigenomic modulators (transcriptional activators and repressors, histone modifiers, DNA (de)methylators, chromatin remodelers) to precisely modulate gene expression without altering DNA. Enables mutation-agnostic, customizable therapies via mix-and-match architecture and is the underlying technology licensed to Kite Pharma for CAR T-cell engineering.

Quantifiable outcome

  • Statistically significant increases in whole-body lean muscle volume - average ~370mL (~0.8 pounds) with individual gains from 0.5 to 1.3 pounds, some muscles gaining 15% lean muscle volume at 6 months
  • +4 more outcomes

Companies that use Epicrispr Biotechnologies

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Epicrispr Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Epicrispr Biotechnologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Forge BiologicscoreTechnology or Integration · 5 May 2025AAV development and manufacturing partnership. Forge Biologics' Columbus, Ohio facility provides adeno-associated virus process development, analytical development, and cGMP manufacturing for EPI-321.
  • Springbok AnalyticscoreTechnology or Integration · 23 April 2025Partnership to integrate AI-powered muscle MRI imaging and analysis into EPI-321 first-in-human clinical trial. Springbok provides automated segmentation and quantification of muscle volume, fat content, and inflammation across dozens of muscle groups.
  • Kite PharmacoreStrategic or Co-development Partner · 31 October 2023Collaboration to develop next-generation CAR T-cell therapies for cancer. Kite tapped Epicrispr's epigenetic editing technology to engineer T cells by modulating gene expression.
  • Pacific Clinical Research NetworkcoreImplementation/ SI/ Consulting PartnerClinical research center in New Zealand conducting EPI-321 first-in-human trial in partnership with Epicrispr. Principal investigator Dr. Richard Roxburgh at University of Auckland.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Epicrispr Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Tune Therapeutics: Tune Therapeutics is an epigenetic editing company developing tunable gene-expression therapies using CRISPR-based platforms. Direct competitor in the same therapeutic modality with overlapping target disease areas including rare genetic disorders.
  • Omega Therapeutics: Omega Therapeutics is an epigenomic programming company developing DNA-encoded regulatory medicines that target genomic "insulators" to tune gene expression. Closely comparable platform approach to GEMS for precise gene-expression modulation without DNA alteration.
  • Chroma Medicine: Chroma Medicine is a direct competitor developing an epigenetic editing platform using dCas9 fused to chromatin regulators, targeting genetic diseases and oncology. Highly comparable technology stack to Epicrispr's GEMS, including mix-and-match epigenetic modulator approach.
  • Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company focused on Duchenne muscular dystrophy and other neuromuscular diseases. Directly competes with EPI-331 in DMD using AAV-delivered approaches, with overlapping clinical and regulatory pathways.

Emerging players

  • Shape Therapeutics: Shape Therapeutics develops RNA editing and AAV-delivered genetic medicines, including platforms that combine RNA editing with epigenetic regulation. Adjacent technology category with shared delivery (AAV) and rare-disease focus, but differentiated at the editing modality.

Broad incumbents

  • Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease-focused biotech with a broad gene therapy and biologics pipeline, including neuromuscular and metabolic programs. Board member Eric Crombez serves as CMO, creating a strategic relationship; competes for the same rare-disease patient populations.
  • Sarepta Therapeutics: Sarepta is the established gene therapy leader for Duchenne muscular dystrophy (DMD), with multiple approved therapies including AAV-delivered Elevidys. Represents the dominant competitor in Epicrispr's EPI-331 DMD indication with deep commercial infrastructure.
  • Krystal Biotech:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Epicrispr Biotechnologies social profiles

Digital presence

Epicrispr Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epicrispr Biotechnologies leadership team

Management profile

Number of profiles

Profiles17 records

Epicrispr Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epicrispr Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epicrispr Biotechnologies

What does Epicrispr Biotechnologies do?

Epicrispr Biotechnologies is a clinical-stage biotechnology company that develops and commercializes epigenetic gene therapies using its proprietary Gene Expression Modulation System (GEMS) platform, which combines compact DNA-binding proteins (CasMINI, CasONYX), customized guide RNAs, and epigenomic modulators to precisely dial gene expression up or down without altering DNA. Its lead clinical asset, EPI-321, is an AAV-delivered epigenetic therapy that re-methylates the D4Z4 region to suppress toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD), currently in Phase 1/2 trials with positive interim muscle volume data. The pipeline additionally includes EPI-331 for Duchenne Muscular Dystrophy and EPI-141 for autosomal dominant Retinitis Pigmentosa 4.

Is Epicrispr Biotechnologies a public or private company?

Epicrispr Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epicrispr Biotechnologies founded?

Epicrispr Biotechnologies was founded in 2022. It employs 51 to 100 people.

Where is Epicrispr Biotechnologies based?

Epicrispr Biotechnologies is headquartered in South San Francisco, United States, in the North America region.

How does Epicrispr Biotechnologies make money?

Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are research Collaborations.

Who are Epicrispr Biotechnologies's main competitors?

Direct peers on record are Tune Therapeutics, Omega Therapeutics, Chroma Medicine and Solid Biosciences. Shape Therapeutics is listed as an emerging player. Broad incumbents are Ultragenyx Pharmaceutical, Sarepta Therapeutics and Krystal Biotech.

Does Epicrispr Biotechnologies have an API?

No public API is recorded for Epicrispr Biotechnologies.

What industry is Epicrispr Biotechnologies in?

Epicrispr Biotechnologies's product category is Epigenetic Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsBeyond Conventional CRISPRFour companies are developing novel gene-editing approaches beyond conventional CRISPR. eGenesis uses CRISPR to engineer pig organs for xenotransplantation, Epicrispr employs epigenetic editing to treat muscular dystrophy, KOMO Biosciences uses integrases for large DNA insertions, and Sumitomo Pharma leverages iPSC-derived therapies. These strategies aim to overcome limitations of traditional CRISPR in delivery and tissue regeneration.Pulse 2.0Epicrispr Biotechnologies Receives $8 Million CIRM Grant To Advance EPI-321 For FSHDEpicrispr Biotechnologies received an $8 million CIRM grant to advance its EPI-321 epigenetic therapy for facioscapulohumeral muscular dystrophy. The funding supports the ongoing Phase 1/2 trial, which reported increases in lean muscle volume and strength after a single administration. Further clinical evaluation is needed to establish safety and efficacy.CNBCBillionaire family offices back healthcare and biotech startups in AugustFamily offices made 52 direct investments in private companies in August, with biotech startups representing about 20% of transactions. Duquesne Family Office backed at least four life sciences companies, including a $90 million Series C for Epicrispr Biotechnologies, while Bezos' family office joined an $188 million Series E for LifeMine Therapeutics. U.S. and European biopharma startups raised $12.6 billion in the first half of 2026, a five-year high.MusculardystrophynewsBiotech raises $90M for late-stage testing of FSHD treatmentEpicrispr Biotechnologies has raised $90 million in financing to support late-stage clinical testing of its epigenetic treatment candidate, EPI-321, for facioscapulohumeral muscular dystrophy. The funding will facilitate pivotal trials and regulatory efforts for the therapy, which targets the DUX4 gene using a viral vector manufactured by partner Forge Biologics. The investment round was led in part by Octagon Capital, whose analyst Anran Li will join Epicrispr's board.WowtaleEpigenetic editing with Epicrisper, $90 million Series C funding raisedEpicrispr has raised $90 million in an oversubscribed Series C funding round, distinguishing itself as the only company in epigenetic editing to demonstrate disease control signals in patients. This financial milestone contrasts with competitors like Tune Therapeutics and nChroma Bio, which have secured significant capital but lack comparable clinical proof-of-concept data.The Pharma LetterEpicrispr Biotechnologies closes $90 Million financingSan Francisco-based Epicrispr Biotechnologies closed a $90 million oversubscribed Series C financing round. The investment was co-led by Octagon Capital and Janus Henderson Investors, with participation from multiple other financial institutions and venture funds including Sanofi Ventures.Pharmaceutical TechnologyEpicrispr, Vaderis secure pivotal study funding for rare disease assets - Pharmaceutical TechnologyBiotechs Epicrispr Biotechnologies and Vaderis Therapeutics have secured significant funding to advance their respective rare disease candidates into pivotal clinical trials. Epicrispr raised $90 million for its gene therapy EPI-321 targeting facioscapulohumeral muscular dystrophy, while Vaderis raised $125 million for engasertib, an oral treatment for hereditary haemorrhagic telangiectasia.Pulse 2.0Epicrispr Biotechnologies Raises $90 Million Series C To Advance Epigenetic Therapy EPI-321Epicrispr Biotechnologies closed an oversubscribed $90 million Series C financing co-led by Octagon Capital and Janus Henderson Investors to advance EPI-321, its investigational therapy for facioscapulohumeral muscular dystrophy, toward pivotal clinical development. The therapy is currently in a first-in-human Phase 1/2 trial that has completed enrollment and demonstrated a favorable safety profile with statistically significant increases in lean muscle volume and biomarker changes consistent with DUX4 suppression following a single administration. The company expects to report additional clinical data later in 2026.American City Business JournalsEpicrispr Bio CEO Amber Salzman raises $90M to fight FSHDEpicrispr Bio CEO Amber Salzman raised $90 million in funding to support advancements in treating facioscapulohumeral muscular dystrophy (FSHD). The funding will likely accelerate the company's clinical development and research efforts.Endpoints NewsEpicrispr secures $90M after early data on epigenetic FSHD treatmentEpicrispr Biotechnologies has secured $90 million in Series C funding following the release of promising early clinical data for its epigenetic treatment of facioscapulohumeral muscular dystrophy (FSHD). The financing supports the company's ongoing development efforts for this rare genetic disorder. This capital raise highlights investor interest in novel epigenetic therapies despite the early stage of the clinical evidence.